CorMedix Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
BERKELEY HEIGHTS, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced financial results for the third quarter and nine months ended September 30, 2022 and provided an update on recent business events.
Related news for (CRMD)
- Biotech Breakouts, Bold Deals, and a Spider Silk Revolution
- CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
- 24/7 Market News Snapshot 20 October, 2025 – CorMedix Inc. (NASDAQ:CRMD)
- CorMedix Announces Strategic Minority Investment in Talphera
- URGENT VENU Update + 52-Week High Movers
